Morning Briefing
Summaries of health policy coverage from major news organizations
Biogen To Pay $900M Over Alleged Drug Kickbacks
After a decade of litigation, Biogen has agreed to pay $900 million to settle a federal whistle-blower lawsuit by a former employee who accused the Cambridge-based drug firm of paying kickbacks to hundreds of doctors to get them to prescribe its multiple sclerosis drugs. Under the terms of the settlement, Biogen will pay more than $843 million to the US government and more than $56 million to 15 states for overbilling Medicare and Medicaid insurance programs. (Saltzman, 9/26)
In other pharmaceutical industry news 鈥
Racial biases continue to be exposed in medical devices clinicians commonly use to evaluate patients. From thermometers to oximeters to X-rays, people of color receive the most inconsistent results, and it's bad for their health. (Hartnett, 9/26)
The partnership, known as the Accelerate Precision Health program, is supported by the Chan Zuckerberg Initiative, an organization created by Facebook founder Mark Zuckerberg and his wife Priscilla Chan to 鈥渟olve some of society鈥檚 toughest challenges.鈥 The grant is part of a multi-year, $500 million investment to support healthcare research advancing racial equity, diversity and inclusion efforts. (Thomas, 9/27)
The era of multimillion-dollar gene therapies has arrived, providing a ray of hope to patients with debilitating diseases 鈥 but also presenting huge affordability challenges. (Owens, 9/26)